Business
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
NEW YORK, May 07, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
About this update from Nuvation Bio Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":864,"height":268,"url":"https://media.zenfs.com/en/business-wire.com/1ba7a6c0f15bdd769b76eee7a5914cf7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S3ghx3tGnJAxk114mKudag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1ba7a6c0f15bdd769b76eee7a5914cf7","width":864,"height":268},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/OSczOLAk.FVeRMzwIDqeTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE3Mjg7aD01MzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1ba7a6c0f15bdd769b76eee7a5914cf7","width":864,"height":268}},"lazy":false},{"type":"text","content":"New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025","length":243,"tagName":"p","attribs":{}},{"type":"text","content":"Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile","length":208,"tagName":"p","attribs":{}},{"type":"text","content":"Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025","length":114,"tagName":"p","attribs":{}},{"type":"text","content":"Company to host a conference call today at 4:30 p.m. ET","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, May 07, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.","length":269,"tagName":"p"},{"type":"text","content":""Nuvation Bio continued to execute with focus in the first quarter as we prepare for the potential U.S. approval and launch of taletrectinib for advanced ROS1-positive NSCLC," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Data recently published in the Journal of Clinical Oncology and presented at the European Lung Cancer Congress and the American ...